Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

NCT04495153 is registered in ClinicalTrials.gov with Candel Therapeutics, Inc. as lead sponsor.

NCT NCT04495153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04495153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients
Lead sponsor
Candel Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 13, 2020
Completion date
December 31, 2026
Enrollment
90 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer